MM-111-13-02-04) Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With or Without Trastuzumab in Patients with `"Traditional" and "Non-Traditional" HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
Description: 

The primary objective of the study is to compare the patient Progression Free Survival (PFS) between the experimental and comparator arms within two distinct patient populations. Patients with "Traditional" and "Non Traditional" HER2 expressing tumors.

Study Number: 

PH 232012

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01774851

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.